# A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

> **NCT04850040** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 15 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Resectable

## Interventions

- **DRUG:** Apatinib Mesylate
- **DRUG:** Camrelizumab
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT04850040
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-06
- **Primary completion:** 2022-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04850040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04850040, "A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04850040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*